Pentobarbital

證據等級: L5

預測適應症: 10 個

Pentobarbital: From Sedative-Hypnotic (Barbiturate) Use to Obesity Disorder

One-Sentence Summary

Pentobarbital is a barbiturate-class central nervous system depressant; the evidence pack does not record a specific approved original indication, and the drug is currently not marketed. The TxGNN model predicts a possible new application for Obesity Disorder, but this is currently supported by only 1 loosely related clinical trial and 20 publications — nearly all of which use pentobarbital merely as an anesthetic or sleep-induction tool in unrelated obesity research rather than evaluating it as a treatment.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (no license/indication text on file; drug historically classified as a barbiturate sedative-hypnotic)
Predicted New Indication	Obesity Disorder
TxGNN Prediction Score	99.99% (rank 573)
Evidence Level	L5
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap DG002, High severity). Based on known pharmacology, Pentobarbital belongs to the barbiturate class of CNS depressants, acting as a positive allosteric modulator of GABA-A receptors to produce sedation, hypnosis, and — at higher doses — anesthesia. This class-level mechanism is well established even though the evidence pack contains no recorded formal indication for this specific compound.

The predicted new indication, Obesity Disorder, has no established mechanistic pathway connecting GABA-A receptor modulation to appetite regulation, leptin signaling, or energy metabolism. The model’s own rationale explicitly notes the absence of a direct pharmacological link: nearly all supporting literature uses pentobarbital solely as an anesthetic/sedative tool to immobilize or euthanize animals during unrelated obesity research (e.g., renal nerve recordings, hypothalamic lesion studies, GH response testing) — not as a treatment being evaluated for obesity itself.

Given this, the high TxGNN similarity score most likely reflects a graph-embedding artifact — frequent literature co-occurrence of “pentobarbital” and “obesity” purely because pentobarbital is a standard laboratory anesthetic used in obesity research — rather than genuine pharmacological plausibility.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01431326	N/A	Completed	3520	Pediatric pharmacokinetic characterization of understudied drugs (including pentobarbital) administered per standard of care; not designed to evaluate obesity treatment (relevance grade C — low).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
5694866	1968	Review	JAMA	Discusses anesthetic management considerations in obese patients; no abstract available, pentobarbital referenced as an anesthetic agent, not a weight-loss therapy.
19321699	2009	Preclinical	Am J Physiol Regul Integr Comp Physiol	Renal sympathetic nerve responses studied in fat-fed rabbits under pentobarbital anesthesia; pentobarbital used only as an anesthetic.
15893702	2005	Preclinical	Autonomic Neuroscience	Gastric electrical stimulation for obesity studied in pentobarbital-anesthetized rats; pentobarbital used as anesthetic tool only.
2674924	1989	Preclinical	Poultry Science	Hypothalamic lesion study of obesity in fowl; pentobarbital’s role is incidental/procedural, not therapeutic.
2145525	1990	Preclinical	Neuroendocrinology	GH response to GRF studied in cafeteria-fed obese rats; pentobarbital is not the agent under investigation.
34072024	2021	Preclinical	Molecules	Brazil nut seed extract tested for anxiolytic/lipid-lowering effects in mice; extract (not pentobarbital) potentiated pentobarbital-induced hypnosis as a secondary sedation assay.
34445005	2021	Preclinical	Nutrients	Garcinia cambogia peel extract screened for arousal effects using the pentobarbital-induced sleep test in a weight-loss supplement study.
28347670	2017	Preclinical	Brain Research	Leptin-mimetic peptide localization study in obese mice; pentobarbital used only for terminal anesthesia/euthanasia.
39563316	2024	Unclassified	Cardiovascular Diabetology	Lipoxin A4 effects on diabetic cardiac dysfunction; relevance to pentobarbital or obesity indication unclear from abstract.
12424750	2003	Unclassified	Medicinal Research Reviews	Review of HISS-dependent insulin action pharmacodynamics; no direct evaluation of pentobarbital as an obesity treatment.

US Market Information

Pentobarbital currently has no marketing authorization on record in this evidence pack (market_status: Not Marketed, total_licenses: 0). No license or product information is available for review.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data are not currently available in this evidence pack (data gap DG001, Blocking severity — TFDA label warnings/contraindications not yet retrieved).

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but the underlying evidence and the model’s own rationale both indicate the link between pentobarbital and Obesity Disorder is weak or spurious — the single trial is unrelated in purpose (pediatric PK), and virtually all supporting literature uses pentobarbital only as an experimental anesthetic tool rather than as a candidate obesity therapy. Evidence Level is L5 (model prediction only). For context, of the 10 candidates in this evidence pack, only rank 5 (“sleep disorder, initiating and maintaining sleep”) has genuine mechanistic plausibility (matches the drug’s known GABA-A sedative-hypnotic class, L4/S1) — yet it is also held back by pentobarbital’s narrow therapeutic index and obsolete safety profile versus modern hypnotics. The remaining candidates (hypervitaminosis, 16p11.2 microdeletion syndrome, obsolete hypertelorism, frontorhiny, monogenic obesity, trichotillomania) have no supporting evidence at all and likely represent embedding artifacts.

To proceed, the following is needed:

TFDA/FDA package insert data: key warnings and contraindications (DG001, blocking)
Detailed mechanism of action documentation (DG002)
A biologically grounded hypothesis linking GABA-A receptor modulation to appetite/energy-metabolism pathways, if this indication is to be pursued further
Purpose-designed preclinical studies evaluating pentobarbital as a therapeutic agent for obesity (not merely as an anesthesia tool in obesity-model research)
A formal reassessment of pentobarbital’s abuse potential and narrow therapeutic index before considering any new indication development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.